AC Immune Operating Income Over Time
| ACIU Stock | USD 2.52 0.01 0.40% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out AC Immune Performance and AC Immune Correlation. Is there potential for Biotechnology market expansion? Will ACIU introduce new products? Factors like these will boost the valuation of AC Immune. If investors know ACIU will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about AC Immune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share | Quarterly Revenue Growth (0.96) | Return On Assets | Return On Equity |
AC Immune's market price often diverges from its book value, the accounting figure shown on ACIU's balance sheet. Smart investors calculate AC Immune's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since AC Immune's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that AC Immune's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AC Immune represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, AC Immune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare AC Immune and related stocks such as Aldeyra, Cellectis SA, and Alto Neuroscience Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALDX | (2.1 M) | (2.1 M) | (1.1 M) | (3.7 M) | (7.3 M) | (12 M) | (18.7 M) | (22.5 M) | (39.7 M) | (63.1 M) | (34.7 M) | (56.2 M) | (62.7 M) | (42.8 M) | (60.1 M) | (54.1 M) | (51.4 M) |
| CLLS | (7.8 M) | (25.3 M) | (26.1 M) | (80.6 M) | (6.4 M) | (30.5 M) | (64 M) | (92.7 M) | (105.1 M) | (123.6 M) | (85.4 M) | (85.4 M) | (89.7 M) | (97.3 M) | (59.6 M) | (53.6 M) | (56.3 M) |
| ANRO | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (29.2 M) | (37.8 M) | (68.6 M) | (68.6 M) | (61.7 M) | (58.7 M) |
| SLN | (933 K) | (5.8 M) | (26.3 M) | (9.1 M) | (12.1 M) | (9.8 M) | (11.9 M) | (14.4 M) | (20.6 M) | (22.7 M) | (35.8 M) | (45.8 M) | (61 M) | (49.6 M) | (63.3 M) | (57 M) | (54.1 M) |
| AMRN | 1.1 M | (44.4 M) | (116.8 M) | (182.1 M) | (96 M) | (98.2 M) | (65.6 M) | (45.6 M) | (108.2 M) | (24.3 M) | (19.7 M) | 10.5 M | (105.9 M) | (67.6 M) | (91.8 M) | (82.6 M) | (78.5 M) |
| CTNM | (28.6 M) | (28.6 M) | (28.6 M) | (28.6 M) | (28.6 M) | (28.6 M) | (28.6 M) | (28.6 M) | (28.6 M) | (28.6 M) | (28.6 M) | (28.6 M) | (22.7 M) | (16.1 M) | (50.9 M) | (45.8 M) | (48.1 M) |
| LYEL | (102.1 M) | (102.1 M) | (102.1 M) | (102.1 M) | (102.1 M) | (102.1 M) | (102.1 M) | (102.1 M) | (102.1 M) | (102.1 M) | (211.9 M) | (214.8 M) | (187.1 M) | (247 M) | (358.8 M) | (322.9 M) | (339 M) |
| MREO | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (36.2 M) | (45.3 M) | (35.2 M) | (50.4 M) | (48.2 M) | (28.3 M) | (53.7 M) | (28.4 M) | (47.4 M) | (42.6 M) | (44.8 M) |
| ANNX | (20.5 M) | (20.5 M) | (20.5 M) | (20.5 M) | (20.5 M) | (20.5 M) | (20.5 M) | (20.5 M) | (19.1 M) | (32.5 M) | (63.5 M) | (130.7 M) | (145.6 M) | (143.7 M) | (154.1 M) | (138.7 M) | (145.6 M) |
| DRTS | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (9.2 M) | (13.8 M) | (32.1 M) | 35.7 M | (36 M) | (32.4 M) | (30.8 M) |
AC Immune and related stocks such as Aldeyra, Cellectis SA, and Alto Neuroscience Operating Income description
Operating Income is the amount of profit realized from AC Immune operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of AC Immune is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| AC Immune | ACIU |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Building B, Lausanne, |
| Exchange | NASDAQ Exchange |
USD 2.52
Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.